Historically, large urban academic centres have conducted the majority of clinical trials, leading to such issues as ...

The conversation centred on the company’s latest developments and strategic direction in cancer therapies, with a particular ...

Summit Pharma has revealed that a second pivotal trial of its Akeso-partnered PD-1xVEGF bispecific ivonescimab has failed to ...

Giusy Di Conza, head of research at small molecule cancer therapeutics firm iOnctura, said ADCs were “heralding a shift ...

Stealth refrained from criticising the FDA's decision on its application, which comes after the agency missed its own ...

The deal with Evopoint boosts Astellas' claudin pipeline as other CLDN18.2 candidates come through the industry pipeline from ...

The award from the Biomedical Advanced Research and Development Authority (BARDA), part of the US Department of Health and ...

The PMCPA also agreed with the complainant that Pfizer had not taken all possible steps to avoid similar breaches in its ...

Drug discovery, and science in general, are fields built on data. Foundation models bring new capabilities by integrating ...

A year ago, MSD and Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan (HER3-DXd) was rejected by ...

Op den Kelder grew up in the Netherlands and received his Bachelor’s degree in International Management from Fontys ...

Angelini is paying $50 million upfront for ex-North American rights to radiprodil, with another $520 million in the offing in ...